FDA Grants Traditional Approval to Iptacopan in Primary IgAN - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Grants Traditional Approval to Iptacopan in Primary IgAN

Novartis reported less annual eGFR decline with iptacopan than placebo over 2 years in the phase 3 APPLAUSE-IgAN trial.

  • By

  • Kathryn Wighton

  • July 17, 2026

  • 2 min

Share

Original Source(s)

FDA Grants Traditional Approval to Iptacopan in Primary IgAN

  • by Kathryn Wighton

  • July 17, 2026

Related Content

Editorial: Advancing immune research in chronic liver diseases through new approach methodologies

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Consultative Medicine Changed Diagnoses

An internist-led consultative care model changed diagnoses for more than half of patients with complex conditions and modified treatment plans in most.